Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05407441	Phase Ib/II	Ipilimumab + Nivolumab + Tazemetostat	Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors	Recruiting	USA	0
NCT06561685	Phase I	LY4050784	A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	Recruiting	USA	1
NCT05286801	Phase Ib/II	Atezolizumab + Tiragolumab	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Recruiting	USA \| CAN \| AUS	0
NCT04741438	Phase III	Ipilimumab + Nivolumab Pazopanib	Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)	Recruiting	FRA	0
NCT02114229	Phase II	Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate	Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)	Active, not recruiting	USA	0
NCT05715281	Phase II	Atezolizumab + Tiragolumab	Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial	Recruiting	USA	0
NCT02601937	Phase I	Tazemetostat	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	Completed	USA \| NLD \| ITA \| GBR \| FRA \| DNK \| DEU \| CAN \| AUS	0
NCT04204941	Phase III	Doxorubicin Doxorubicin + Tazemetostat	Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma	Recruiting	USA \| GBR \| CAN	1
NCT02601950	Phase II	Tazemetostat	A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma	Completed	USA \| ITA \| GBR \| FRA \| DEU \| CAN \| BEL \| AUS	1
NCT03654716	Phase I	ALRN-6924 + Cytarabine ALRN-6924	Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer	Completed	USA	0
NCT04779151	Phase II	Dostarlimab-gxly + Niraparib	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)	Suspended	FRA	0
NCT03213665	Phase II	Tazemetostat	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT06560645	Phase I	PRT7732	A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation	Recruiting	USA \| AUS	0
NCT04611139	Phase I	Pembrolizumab + Seclidemstat	Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers	Withdrawn	USA	0
NCT05687136	Phase I	M1774 + Peposertib	Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	Recruiting	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT05495464	Phase I	Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab	A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma	Recruiting	USA	0
NCT05861050	Phase Ib/II	Glofitamab-gxbm + Lenalidomide + Obinutuzumab + Venetoclax	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	Recruiting	USA	0
NCT05639751	Phase I	Docetaxel + PRT3789 PRT3789	PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation	Recruiting	USA \| NLD \| FRA \| ESP	1
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0

Gene Detail

Contact

Filtering

Sorting